Comparation of Treatment Strategies for OVF: Teriparatide Injection and PVP

Nanfang Hospital, Southern Medical University

Status: Active, not recruiting

Conditions: Quality of Life; Osteoporosis, Postmenopausal; Vertebral Fracture

Treatments: Procedure: PVP; Drug: Alendronate; Drug: Teriparatide

Study type: Observational

Funder types: Other

Identifiers

NCT03692143

NFEC-2018-067

Details and patient eligibility

About

This study aimed to compare teriparatide treatments and PVPs, focusing on its effects on life qualities and effect/coast ratio and evaluate which method is better for patients.

Full description

Osteoporosis and osteoporotic vertebral fracture (OVF)s are the common diseases that affect the qualities of senior people. The general treatments for OVFs including percutaneous vertebroplasty (PVP) operation and conservative treatments with pain killers. But with the widely used methods, the life quality of patients were still not satisfied. Teriparatide has been proven to increase bone qualities in patients with severe osteoporosis and reduced the fracture possibilities. The investigators' previous clinical observation found teriparatide could be applied to treat fresh OVFs.

90 participants who diagnosed fresh OVFS were included in the trial. After they received each of three kinds of interventions mentioned in this study, The investigators followed up all these cases. Once 30 cases goal reaches in a certain group, the data collection in that special will stop automatically. The quality of life, pain score and BMDs will be evaluated in certain time during the trial.

Enrollment: 90 estimated patients

Sex: Female

Ages: 49 to 99 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• 1.postmenopausal women with osteoporotic fractures 2.treated with teriparatide 3.or treated with vertebroplasty 4.or treated with teriparatide after vertebroplasty 5.or treated with Fosamax 6. willing to anticipate the trial

Exclusion criteria

• Serious other illness or disease which effecting quality of life occurs later in treatment
• unwilling to anticipate the trial

Trial design

90 participants in 3 patient groups

teriparatide group

Description:

The group of postmenopausal women who diagnosis with osteoporotic fractures treated with teriparatide

Treatment:

Drug: Teriparatide

PVP group plus alendronate

Description:

The group of postmenopausal women who diagnosis with osteoporotic fractures treated with vertebroplasty. Then alendronate was prescribed.

Treatment:

Procedure: PVP

Drug: Alendronate

teriparatide and PVP group

Description:

The group of postmenopausal women who diagnosis with osteoporotic fractures treated with teriparatide after vertebroplasty

Treatment:

Procedure: PVP

Drug: Teriparatide